Gilead Sciences Inc. closed $8.74 short of its 52-week high ($87.87), which the company achieved on January 19th.

Gilead Sciences Inc. closed $8.17 short of its 52-week high ($87.87), which the company reached on January 19th.

Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program ...

Gilead Sciences reported good quarterly results and in the last few weeks, the stock rallied higher. Find out more on GILD ...

NORTHAMPTON, MA / ACCESSWIRE / September 4, 2024 / Transformative medicines have the greatest impact when they reach the ...

Very pleased to be hosting Gilead this afternoon, sorry. And we have joining us Dan O'Day, the company's Chairman and CEO; and Andy Dickinson, the company's CFO. Thank you both for taking time out of ...

Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Gilead Sciences (GILD – Research Report). The associated price ...

Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $74.00. The company’s shares closed yesterday at $79.70.

Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead Sciences ...

Gilead paid $320 million to buy out Johnson & Johnson's potential 8% royalty on the primary biliary cholangitis drug developed by CymaBay. A liver disease drug at the center of Gilead Sciences Inc ...